Corydine

Corydine is a HIV-1 reverse transcriptase inhibitor and μ-opioid receptor (MOR) agonist, with an IC₅₀ of 356.7 μg/mL against HIV-1 reverse transcriptase, an EC₅₀ of 0.51 μM for MOR, and a K_i of 2.82 μM for MOR. Corydine produces antinociceptive effects by inhibiting acetic acid-induced writhing behavior in a MOR-dependent manner. Corydine inhibits the proliferation of cancer cells, mitogen-stimulated lymphocytes and IL-2-dependent cells. Corydine can be used in studies related to human immunodeficiency virus infection, visceral pain, leukemia, melanoma, bladder cancer and colon adenocarcinoma^[1][2][3]. In Vitro:Corydine (5-450 μg/mL; 1 h) inhibits the enzymatic activity of HIV-1 reverse transcriptase in vitro, with an IC₅₀ of 356.8 μg/mL, and reduces the enzymatic activity by 40% at a concentration of 450 μg/mL^[1].
Corydine (60 min) binds to and moderately activates the human μ-opioid receptor expressed on the cell membrane of CHO-hMOR, with a K_i value of 2.82 μM and an EC₅₀ value of 0.51 μM^[2].
Corydine (24 h) inhibits the proliferation of P388 and L1210 leukemia cells as well as Colon 26 colon cancer cells, with IC₅₀ values of 23.3 μg/mL, 25.9 μg/mL, and 8.4 μg/mL, respectively^[3].
Corydine (44 h) inhibits concanavalin A (Con A)-induced splenic lymphocyte proliferation in mice, with an IC₅₀ of 15.7 μg/mL^[3].
Corydine (20 h) inhibits the proliferation of mouse IL-2-dependent CTLL2 cells in vitro, with an IC₅₀ of 10.5 μg/mL^[3]. In Vivo:Corydine (5 mg/kg; s.c.; single dose) produces a 51% reduction in acetic acid-induced writhing in male CD1 mice via a mu opioid receptor-dependent mechanism^[2].